We performed separate nested case-control analyses in two national cohorts of women who received chemotherapy for incident breast cancer. Cohorts were identified from Medicare (≥ 65 years of age) and ...
CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study This study includes the PanCareSurFup and ProCardio cohort of ≥ 5 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results